Novo Nordisk A/S Class B
NONOF
Market Cap$435.75B
Close$
$127.12
0.5% upside
Current Fair Value
0.5% upsideUndervalued by 0.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $435.75 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $12.4 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.0 |
| Outstanding Shares | 3,435,128,000 |
| Avg 30 Day Volume | 25,447 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Novo Nordisk A/S
CEO: Lars Fruergaard Jørgensen Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The...